In a clinical study with oral gemcitabine (2 ¶,2 ¶-difluorodeoxycytidine, dFdC), 2 ¶,2 ¶-difluorodeoxyuridine (dFdU) was extensively formed and accumulated after multiple oral dosing. Here, we have investigated the in vitro cytotoxicity, cellular uptake, efflux, biotransformation, and nucleic acid incorporation of dFdC and dFdU. Short-term and long-term cytotoxicity assays were used to assess the cytotoxicity of dFdC and dFdU in human hepatocellular carcinoma HepG2, human lung carcinoma A549, and Madin-Darby canine kidney cell lines transfected with the human concentrative or equilibrative nucleoside transporter 1 (hCNT1 or hENT1), or empty vector. Radiolabeled dFdC and dFdU were used to determine cellular uptake, efflux, biotransformation, and incorporation into DNA and RNA. The compounds dFdC, dFdU, and their phosphorylated metabolites were quantified by high-performance liquid chromatography with UV and radioisotope detection. dFdU monophosphate, diphosphate, and triphosphate (dFdU-TP) were formed from dFdC and dFdU. dFdU-TP was incorporated into DNA and RNA. The area under the intracellular concentration-time curve of dFdC-TP and dFdU-TP and their extent of incorporation into DNA and RNA inversely correlated with the IC 50 of dFdC and dFdU, respectively. The cellular uptake and cytotoxicity of dFdU were significantly enhanced by hCNT1. dFdU inhibited cell cycle progression and its cytotoxicity significantly increased with longer duration of exposure. dFdU is taken up into cells with high affinity by hCNT1 and phosphorylated to its dFdU-TP metabolite. dFdU-TP is incorporated into DNA and RNA, which correlated with dFdU cytotoxicity. These data provide strong evidence that dFdU can significantly contribute to the cytotoxicity of dFdC. [Mol Cancer Ther 2008;7(8):2415-25] 
Introduction
Gemcitabine (2 ¶,2 ¶-difluorodeoxycytidine, dFdC) has proven antitumor activity both in vitro and in vivo (1 -6) . dFdC is transported into cells by human nucleoside transporters (7) and is intracellularly phosphorylated by deoxycytidine kinase to its monophosphate (dFdC-MP) and subsequently phosphorylated to its active diphosphate (dFdC-DP) and triphosphate (dFdC-TP) metabolites (5) . dFdC-TP competes with the natural substrate dCTP for incorporation into DNA (8) , thereby inhibiting DNA synthesis and blocking cells in the early S phase (6) . dFdC-DP inhibits ribonucleotide reductase (9) , ultimately leading to depletion of dCTP pools and facilitating DNA incorporation of dFdC-TP. Moreover, dFdC can potentiate its own cytotoxic effect via other pathways (10, 11) . Alternatively, dFdC is deaminated by cytidine deaminase (CDA, EC 3.5.4.5; ref. 10) , which is highly expressed in human liver (12) to 2 ¶,2 ¶-difluorodeoxyuridine (dFdU), of which the activity is uncertain. The chemical structures of dFdC and dFdU and the biotransformation and mechanisms of action of dFdC are depicted in Fig. 1 .
dFdC is a high-affinity substrate for the human concentrative nucleoside transporter type 1 (hCNT1; apparent K m f12 -36 Amol/L) and is transported at lower affinity by the human equilibrative nucleoside transporter type 1 (hENT1; apparent K m f120 -200 Amol/L; refs. 7, 13) . It has been shown that the uptake of dFdC and its cytotoxicity significantly decreased following coadministration with nitrobenzylmercaptopurine riboside, an inhibitor of hENTmediated transport (14) . Expression of hCNT1 was shown to correlate with toxicity of dFdC in vitro in human pancreatic adenocarcinoma cell lines (15) and expression of hENT1 with overall survival in patients with pancreatic cancer (16) . hENT1 is a ubiquitous transporter with significant variability in tissue abundance (17) , whereas hCNT1 is considered to have more restricted distribution, with high expression in liver and kidney (18) .
In a clinical study on continuous low-dose oral dFdC in patients with advanced solid tumors, dFdU was extensively formed via first-pass metabolism and accumulated, most likely in the liver (19) . One patient treated with 8 mg of oral dFdC once daily for 14 days of a 21-day cycle experienced lethal hepatotoxicity. Pathologic examination revealed severe drug-induced liver necrosis.
We hypothesized that dFdU might contribute to the toxicity and/or antitumor activity of dFdC and might become hepatotoxic after liver accumulation following chronic oral dFdC administration. We speculated that dFdU is phosphorylated to its triphosphate (dFdU-TP) and subsequently incorporated into DNA and/or RNA. Furthermore, our hypothesis was that dFdU is taken up by cells with high affinity by hCNT1.
The aims of this study were to investigate the cytotoxicity, effects on cell cycle distribution, cellular uptake, efflux, biotransformation, and nucleic acid incorporation of dFdU and its parent compound dFdC in vitro using human hepatocellular carcinoma HepG2, human lung carcinoma A549, and Madin-Darby canine kidney (MDCK) cells transfected with either hCNT1, hENT1 or empty vector.
Materials and Methods
Antibodies FITC-labeled goat anti-rabbit IgG antibody was purchased from Molecular Probes, Inc. Mouse anti-bromodeoxyuridine was purchased from Dakocytomation. Antimouse IgG-FITC was derived from Sigma-Aldrich Chemie GmbH.
Reagents dFdC, dFdU, dFdC-MP, dFdC-DP, dFdC-TP, dFdU-MP, dFdU-DP, dFdU-TP, and CDA (activity: 2 Amol/min/mg for cytidine) were kindly provided by Eli Lilly and Company. Chemical structures of dFdC and dFdU and proposed biotransformation and pharmacologic actions of dFdC and its metabolites. Transport of dFdC by human nucleoside transporters and phosphorylation by deoxycytidine kinase (dCK ) to its monophosphate (dFdC-MP ) and by human nucleoside monophosphate and diphosphate kinases (NMPK and NDPK ) into its diphosphate (dFdC-DP ) and triphosphate (dFdC-TP ) metabolites. dFdC-TP is incorporated into RNA and particularly into DNA, thereby competing with dCTP for incorporation. dFdC-DP inhibits ribonucleotide reductase (RR ), which inhibits the conversion of CDP to dCDP and depletes dCTP pools, resulting in less inhibition of deoxycytidine kinase and elevation of the intracellular dFdC-TP/dCTP ratio, ultimately resulting in enhanced incorporation of dFdC-TP into DNA. dFdC is deaminated by CDA to dFdU. dFdC-MP is converted to difluorodeoxyuridine monophosphate (dFdU-MP ) by deoxycytidylate deaminase (dCMPD ). dFdC-TP can inhibit dCMPD, thereby stimulating its own formation. Novel pathways found in this study (arrows in boldface ): dFdU is transported into cells by hCNT1 and phosphorylated to its monophosphate (dFdU-MP ), diphosphate (dFdU-DP ), and its triphosphate (dFdU-TP ), which is incorporated into DNA and RNA. cultured in RPMI 1640, DMEM, and modified Eagle's MEM, respectively. Medium was supplemented with 100 units/mL of penicillin, 100 Ag/mL of streptomycin, and 10% fetal bovine serum. All cell lines were routinely tested to confirm that they were free of Mycoplasma. All experiments were done with exponentially growing cells. Cells were treated with drugs after a period of 12 h for the cells to attach.
Sulforhodamine B Cytotoxicity Assay Cells in 200 AL/well were plated in 96-well plates and dFdC and dFdU were added in serial dilutions for 48, 72, and 96 h. Cells were washed and stained with sulforhodamine B (21, 22) . Extinction was measured at 540 nm with a microplate reader (BioTek Instruments). The data were fitted to a sigmoidal concentration-response curve, and cytotoxicity was determined by calculation of the inhibitory concentration at 50% cell death (IC 50 ) using GraphPad prism version 4.0 for Windows (GraphPad Software). Control wells (untreated) were set at 100% survival.
Clonogenic Survival Assay Cells in 2 mL medium were plated in six-well plates and dFdC and dFdU were added at varying concentrations. Cells were allowed to form colonies over a maximal period of 14 days after the addition of drugs, which were subsequently fixed and stained with 0.2% crystal violet/ 2.5% glutardialdehyde. The number of colonies was counted with a Colcount (Oxford Optronix) and visually confirmed under a light microscope to contain at least 50 cells. Cell survival was corrected for plating efficiency.
Cell Cycle Analysis HepG2 and A549 cells in 2 mL of medium were plated in six-well plates. dFdC and dFdU were added for 8, 24, 48, and 72 h and labeled with iododeoxuridine (23) . In brief, nuclei were isolated and incubated with a mouse antibromodeoxyuridine antibody, which binds to iododeoxuridine (1:50), followed by a 30-min incubation with FITC-conjugated anti-mouse antibody (1:50). Finally, propidium iodide was added to stain total DNA. Flow cytometry was carried out using a FACScan flow cytometer.
Nucleoside and Nucleotide Extraction and Analysis Separation, identification, and quantification of dFdC, dFdU, dFdC-MP, dFdC-DP, dFdC-TP, dFdU-MP, dFdU-DP, and dFdU-TP were done using ion-pairing reversed phase high-performance liquid chromatography (Beckman Coulter, Inc.) with UV and off-line radioisotope detection (Packard, Instrument Co., Inc.). A C18 HDO column, 5 Am, 150 Â 4.6 mm (Uptisphere, Interchrom) was used with a column temperature of 40jC, a 1:1 mixture of Ultima-flow and mobile phase, and a flow rate of 1.0 mL/min. The mobile phase consisted of a mixture of eluent A [80 mmol/L potassium phosphate (pH 7.0), 11 mmol/L tetrabutylamine, and 1.0% methanol] mixed with eluent B [80 mmol/L potassium phosphate (pH 7.0) and 10% methanol] in the following gradient: t = 0 to 10 min, 17% B; 10 to 65 min, 22% B; 65 to 85 min, 100% B; and 85 to 90 min, 17% B. System suitability was assessed using a mixture of reference standards of dFdC, dFdU, dFdC-MP, dFdC-DP, dFdC-TP, dFdU-MP, dFdU-DP, and dFdU-TP prior to each sequence.
Radioactivity was determined with a Tri-Carb 2800 TR liquid scintillation analyzer (Perkin-Elmer). Metabolites were quantified based on the radioactivity of the metabolite peak relative to the radioactivity of [
H]dFdC or [
3 H]dFdU with correction for the total amount of the drug. The concentration of cellular protein was determined by the BioRad Protein Assay (24) and was used to correct for differences in the amount of isolated cells between samples. In HepG2 and A549 cells, cell number and cell volume were determined by a Casy 1 cell counter (Schärfe System GmbH) to be able to calculate micromolar concentrations of dFdC-TP.
The nucleosides and nucleotides eluted at the following retention times: t = 6.7 min (dFdC), 10. H]dFdC (1.0 mCi/mL), 80 AL of CDA (134 Ag/mL), and 8.9 mL of 10 mmol/L TrisHCl (pH 7.5) was incubated for 60 min at 37jC. The solution was snap-frozen on a dry ice/ethanol bath, freeze-dried, and the pellet was dissolved in 500 AL of eluent [10 mmol/L NaH 2 PO 4 , 2.0% methanol (pH 6.0)] and injected onto the high-performance liquid chromatograph. [ 3 H]dFdU was identified with UV and radioisotope detection as described above. The reference compounds dFdC and dFdU were used prior to each sequence to assess system suitability. The elution times for dFdC and dFdU were 15 and 26 min, respectively. The [ 3 H]dFdU fraction was collected, freeze-dried, and the pellet was dissolved in 1.0 mL of Milli-Q. The recovery was calculated based on the radioactivity of [ 6 dpm/well) complemented with cold dFdC and dFdU, respectively, to total concentrations of 0.5 and 5.0 Amol/L. In HepG2 cells, it was able to measure intracellular drug at the lower IC 50 of 5 nmol/L dFdC, which was compared with the IC 50 of 500 Amol/L dFdU. dFdC was also coincubated with 100 Amol/L of tetrahydrouridine, a competitive inhibitor of CDA (25 -27) , to reduce deamination of dFdC to dFdU to better compare the relative toxicity of dFdC with dFdU. Experiments were stopped, medium was collected, and cells were washed thrice with 10 mL of ice-cold PBS. Subsequently, cells were scraped in 10 mL ice-cold PBS, transferred into a 15 mL tube, and centrifuged at 1,100 Â g at 0jC for 5 min. The supernatant was removed and cells were resuspended into 200 AL ice-cold PBS. Twenty microliters was used to determine the protein concentration. The remaining solution was mixed with methanol to a final concentration of 60% and placed at À20jC for 2 h to precipitate proteins and to extract dFdC, dFdU, and their phosphorylated metabolites. After centrifugation at 21,000 Â g for 5 min, the supernatant was freeze-dried, resuspended in 240 AL of eluent A, sonificated for 5 min, and centrifuged at 21,000 Â g for 5 min. The supernatant was collected for analysis of dFdC, dFdU, and phosphorylated metabolites by highperformance liquid chromatography. A comparable procedure was done for the medium.
Incorporation of dFdC-TP and dFdU-TP into DNA and RNA Cells in 10 mL of medium were plated in 8-cm dishes and incubated for 24 h with [ dpm/dish), both complemented with cold drugs to total concentrations of 0.5 Amol/L (as well as the IC 50 concentrations of 5 nmol/L dFdC and 500 Amol/L dFdU in HepG2 cells). After termination of the experiments, medium was discarded, and cells were washed thrice with 10 mL of ice-cold PBS. Subsequently, cells were scraped in 10 mL of ice-cold PBS, transferred into a 15 mL tube, centrifuged at 1,100 Â g at 0jC for 5 min and the supernatant was discarded. From the remaining cell pellet, DNA and RNA were purified using a QIAamp DNA Mini Kit and RNeasy Mini Kit, respectively (Qiagen, Inc.). Purity was determined by a Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies, Inc.). After purification, 80 AL of the DNA/RNA solution (maximal 100 Ag DNA/ RNA) was diluted with 420 AL of 50 mmol/L ammonium acetate (pH 5.0) and digested by the addition of 6 AL of nuclease P 1 (0.5 units/AL) at 60jC for 3 h. Final solutions were freeze-dried, resuspended in eluent A, centrifuged at 21,000 Â g for 5 min, and the supernatant was collected for quantification of dFdC-MP and dFdU-MP and determination of the amount of incorporated dFdC-TP and dFdU-TP. Transport of dFdC and dFdU by hCNT1 MDCK-hCNT1 and MDCK-mock cells in 1.0 mL medium/well were plated in 24-well plates. Transport experiments were carried out in sodium-containing transport buffer [20 mmol 
3 H]dFdU (150,000 dpm/well) both complemented with cold dFdC and dFdU, respectively, at varying concentrations were added for 15 min at 37jC. Experiments were stopped, medium was discarded, and cells were washed thrice with 1.0 mL of ice-cold PBS. Cells were lysed in 500 AL of 1N NaOH for 30 min at 37jC, resuspended, radioactivity was counted and protein concentration was determined.
Efflux of dFdC and dFdU HepG2 and A549 cells in 1.0 mL medium/well were plated in 24-well plates. Cells were loaded with [ 3 H]dFdU for 4 h complemented with cold drugs to 5 Amol/L. The short period of time and relatively high dFdC concentration were chosen to prevent the metabolism of dFdC, and to obtain measurable amounts of dFdC. After loading the cells, medium was replaced by fresh medium and samples were taken at t = 0, 5, 10, 30, and 60 min. Cells were washed thrice, scraped and resuspended in ice-cold PBS, centrifuged at 21,000 Â g for 5 min, the supernatant was discarded, and cells were resuspended in 200 AL of ice-cold PBS. The protein concentration was determined and nucleosides and nucleotides were quantified.
In vitro Pharmacokinetic and Statistical Analysis The cellular pharmacokinetic variables of dFdC, dFdU, dFdC-MP, dFdC-DP, dFdC-TP, dFdU-MP, dFdU-DP, and dFdU-TP were determined by noncompartmental analysis using WinNonLin (version 5.0.1, Pharsight Corporation). The area under the intracellular concentration-time curve (AUC) up to the last measured concentration-time point (AUC 0 -24 ) was determined using the trapezoidal method. Furthermore, the maximal observed drug concentration (C max ) and the terminal half-life (t 1/2 ) were determined. Pharmacokinetic variables and IC 50 values were reported as mean F SD (n z 3). Two-sided unpaired Student's t tests were applied on the log-transformed values of the IC 50 . Relationships between (a) the dFdC or dFdU concentration that was added to HepG2 cells and the intracellular levels of metabolites, (b) the AUC of dFdC-TP/dFdU-TP and the IC 50 of dFdC/dFdU, (c) the extent of incorporation into DNA/RNA of dFdC-TP/dFdU-TP and the IC 50 of dFdC/ dFdU, and (d) the AUC of dFdC-TP/dFdU-TP and the extent of incorporation into DNA/RNA were assessed by scatter plots and Spearman correlation coefficients. Statistical analysis was done using SPSS 15.0 (SPSS, Inc.). Differences were considered to be statistically significant at P < 0.05.
Results

Cytotoxicity of dFdU Is Highly Dependent on Time Period of Drug Exposure and Influenced by Expression of hCNT1
The IC 50 of dFdC and dFdU decreased 13-fold and 196-fold, respectively, in HepG2 cells and 3.5-fold and 48-fold, respectively, in A549 cells when the exposure time was increased from 72 hours to 14 days ( Table 1 ). The IC 50 for dFdC at 72 h was f94,000-fold, 113,000-fold, and 2,500-fold lower than for dFdU in HepG2, A549, and MDCKhCNT1 cells, respectively. Tetrahydrouridine lowered the IC 50 of dFdC f2-fold in HepG2 and A549 cells (P = 0.005 for both) and did not influence dFdU cytotoxicity. The cytotoxicity at 72 hours for dFdC and dFdU was f3-fold to 4-fold higher in HepG2 compared with A549 cells (P = 0.005 for dFdC and P < 0.001 for dFdU). hENT1-MDCK cells had a 3-fold higher sensitivity to dFdC compared with mock cells (P = 0.032) without significant differences for dFdU (Table 1) . IC 50 values at 72 hours were significantly lower for dFdC (8-fold, P = 0.015) and dFdU (26-fold, P < 0.001) in hCNT1-overexpressing cells compared with mock cells (Table 1 ). These data show that dFdC cytotoxicity is significantly affected by CDA activity and expression of hENT1 and dFdU cytotoxicity is significantly influenced by expression of hCNT1.
dFdU-TP Is Intracellularly Formed and its Accumulation Correlates with dFdU Cytotoxicity
As depicted in Fig. 2A and C and Table 2 , dFdU, dFdC-TP, and dFdU-TP had a long t 1/2 , demonstrating the long retention of these metabolites in HepG2 cells. Coadministration of dFdC with tetrahydrouridine in HepG2 cells resulted in a 1.5-fold to 2-fold increase in intracellular dFdC, dFdC-MP, dFdC-DP, and dFdC-TP, consistent with the somewhat higher cytotoxicity of dFdC when coadministered with tetrahydrouridine. The metabolites dFdU-MP, dFdU-DP, and dFdU-TP were the only detected compounds following incubation with dFdU ( Fig. 2D; Table 2 ). This shows that dFdU itself enters the cell and is further phosphorylated to its metabolites (Fig. 1) The nucleotides of dFdU contributed to 47%, 15%, and 8% of the total intracellular drug content following dFdU treatment in HepG2, A549, and MDCK cells, respectively, demonstrating relatively high phosphorylation of dFdU in HepG2 cells. In HepG2 cells, the AUC of dFdC-TP increased with the concentration of dFdC in the range from 5 nmol/L to 0.5 Amol/L to 5 Amol/L (r = 0.949, P = 0.001). Intracellular drug accumulation increased up to 20 Amol/L of dFdC reaching a plateau at higher concentrations (data not shown). The AUC of dFdU-TP, after incubation with dFdU, increased linearly in the range from 0.5 Amol/L to 5 Amol/L to 500 Amol/L (r = 0.949, P = 0.001).
In HepG2 cells, the AUC of dFdU-TP after treatment at the IC 50 of 500 Amol/L dFdU, was approximately 7-fold higher than the AUC of dFdC-TP after treatment at the IC 50 of 5 nmol/L dFdC ( Fig. 3A and B ; Table 2 ).
The pattern of accumulation of dFdC and its metabolites was dependent on the incubation concentration of dFdC both in HepG2 and MDCK-hCNT1 cells. In HepG2 cells, for example, dFdC, dFdU, dFdC nucleotides, and dFdU nucleotides contributed 5%, 1%, 82%, and 12%, respectively, to the total recovered intracellular drug content after treatment with 5 nmol/L of dFdC, whereas these values were 1%, 0.06%, 98% and 0.94%, respectively, following incubation at 0.5 Amol/L dFdC. Additionally, C max of DNA (pmol/Amol) n.a. n.a. n.a. n.a. 400 F 60 n.a. n.a.
DNA (pmol/Amol) n.a. n.a. n.a. n.a. n.a. n.a. n.a. 20 F 2.0 RNA (pmol/Amol) n.a. n.a. n.a. n.a. n.a. n.a. n.a. 10 F 2.0 (E -H) and dFdC 0 to 100 nmol/L (I -L). Similar to dFdC, dFdU caused a concentration-dependent arrest in the early S phase. These effects were also time-dependent and similar results were found in A549 cells (data not shown). dFdU-TP Is Incorporated into DNA and RNA and its Incorporation Correlates with the Cytotoxicity of dFdU Both dFdC-TP and dFdU-TP were incorporated into nucleic acids favoring DNA over RNA (Table 2) . Strong inverse correlations were found for the IC 50 of dFdC with the amount of incorporated dFdC-TP into DNA (r = À0.856, P = 0.003) and RNA (r = À0.933, P = 0.001) and for the IC 50 of dFdU following dFdU treatment with the amount of incorporated dFdU-TP into DNA (r = À0.850, P = 0.004) and RNA (r = À0.910, P = 0.001; Fig. 3F and G) . As expected, significant positive correlations were found for the AUC of dFdC-TP and the extent of incorporation of dFdC-TP into DNA (r = 0.867, P = 0.002) and RNA (r = 0.933, P = 0.001) and for the AUC of dFdU-TP after treatment with dFdU with the extent of incorporation of dFdU-TP into DNA (r = 0.942, P = 0.001) and RNA (r = 0.900, P = 0.001).
In HepG2 cells treated at IC 50 concentrations of dFdC or dFdU, only a 1.3-fold difference (P = 0.051) was observed in DNA incorporation of dFdC-TP after dFdC treatment and DNA incorporation of dFdU-TP after dFdU treatment (Fig. 3C) , suggesting equal intrinsic toxicity of dFdC-TP and dFdU-TP.
Transport of dFdU and dFdC Is Mediated by hCNT1
The uptake of dFdC and dFdU significantly increased with the concentration of the drugs (Fig. 4) . Transport of both dFdC and dFdU was significantly enhanced in the presence of sodium, required as cotransporter for hCNT1-mediated transport (Fig. 4A) . As expected, uptake of dFdC and dFdU in MDCK-hCNT1 cells in the absence of sodium decreased to levels comparable with those in the MDCKmock cells (Fig. 4A and B) .
dFdU and dFdC Are Effluxed After loading the HepG2 and A549 cells and release in drug-free medium, intracellular concentrations of dFdC rapidly decreased to 10% of the initial concentration within 10 minutes without significant formation of dFdU and phosphorylated metabolites. In HepG2 cells, the elimination pattern of dFdC was biphasic with a rapid elimination during the first 10 minutes (t 1/2,a = 2.6 minutes) followed by a slower elimination from 10 to 60 minutes (t 1/2,h = 28 minutes). Elimination of dFdU was also biphasic with an initial rapid elimination (t 1/2,a = 9.2 minutes) followed by a slower elimination (t 1/2,h = 90 minutes). Thus, dFdC and dFdU were rapidly effluxed with a slower elimination rate of dFdU compared with dFdC.
Discussion
This is the first study that shows the formation of dFdU-MP, dFdU-DP, and dFdU-TP from dFdC and dFdU. It shows that dFdU is a good substrate for hCNT1 and is intracellularly phosphorylated and incorporated into nucleic acids. The AUC and extent of incorporation of dFdU-TP and dFdC-TP into DNA and RNA positively correlate with the cytotoxicity of dFdU and dFdC, respectively. The IC 50 for dFdU of 2.5 Amol/L (f660 ng/mL) following 14 days of incubation was of the same order of magnitude as the plasma concentrations of dFdU (f700 ng/mL) in patients treated with multiple low doses of oral dFdC in our phase I study.
The IC 50 values for dFdC and dFdU in this study were somewhat higher compared with the IC 50 values at 48 hours for dFdC of 0.6 to 11 nmol/L in A2780, C26-10, and WiDr cell lines (29), and the IC 50 value at 24 hours for dFdU of 252 Amol/L in H292 cells (30) . This could be due to differences in expression of uptake and efflux transporters and in metabolic enzymes. Treatment with dFdU clearly caused an arrest of cells in the early S phase, consistent with findings in ECV304 and H292 cells (31) .
The relatively high amount of dFdU nucleotides in HepG2 cells treated at 5 nmol/L dFdC (corresponding with 10 Amol/L dFdC-TP) compared with the higher 0.5 Amol/L dFdC concentration (corresponding with 556 Amol/L dFdC-TP) was possibly due to less inhibition of dCMPD by dFdC-TP, leading to increased deamination of dFdC-MP. Of note, dFdC-TP concentrations of 460 Amol/L were shown to cause 50% inhibition of dCMP deaminase activity (11) . The intracellular concentrations of dFdC-DP of In patients who were treated with 8 mg of oral dFdC in our phase I study, plasma concentrations of dFdC were close to 1 ng/mL (f 4 nmol/L) and the AUC 0 -24 of dFdC-TP was 78 h pmol/mg protein in peripheral blood mononuclear cells, which was comparable to the AUC 0 -24 in HepG2 cells of 45 h pmol/mg protein after 5 nmol/L of dFdC. The AUC 0 -24 of dFdU-TP in peripheral blood mononuclear cells was 129 h pmol/mg protein and increased to 927 h pmol/mg protein following daily oral dosing for 14 days, which was 182-fold higher compared with the dFdU-TP AUC 0 -24 of 5.1 h pmol/mg protein after 5 nmol/L of dFdC and 3-fold higher than the dFdU-TP AUC 0 -24 of 309 h pmol/mg protein after 500 Amol/L of dFdU in HepG2 cells. Thus, in patients, there is a relatively high exposure to dFdU-TP in peripheral blood mononuclear cells, possibly due to differences in uptake, efflux, and biotransformation of dFdC and/or dFdU between human peripheral blood mononuclear cells and solid tumor cell lines.
Both dFdC and dFdU were effluxed from HepG2 and A549 cells, possibly by hENT1, which was found to be expressed in both cell lines in the quantitative-PCR experiments (data not shown). The presence of dFdC-MP, dFdU-MP, and dFdU-TP in the medium suggests that cells are able to efflux nucleoside phosphates. To our knowledge, only multidrug resistance proteins (MRP4 and MRP5) were shown to transport nucleoside monophosphates but with low affinity and without having significant effects on resistance to dFdC (32 -34) . Further studies should elucidate possible efflux transporters for these compounds. Theoretically, tetrahydrouridine might have inhibited the uptake of dFdC and dFdU, in part, by inhibition of human nucleoside transporters following simultaneous administration. However, this is unlikely based on the increase in uptake and cytotoxicity of dFdC after coincubation with tetrahydrouridine in this study, consistent with previous findings for cytarabine plus tetrahydrouridine in hepatocytes (35) .
This study showed high transport of dFdU by hCNT1, which is highly expressed in liver (18, 36) , kidney (37, 38) , and intestine (39, 40) . This might cause the (re)uptake of dFdU into the liver of patients, leading to high exposures to dFdU and its nucleotides in the liver for prolonged periods of time. Cytotoxicity of dFdU in MDCK-hCNT1 cells largely exceeded cytotoxicity in hENT1 cells, consistent with the high transport of dFdU by hCNT1 (7, 15) .
This study clearly showed the phosphorylation of dFdU to its nucleotides in all tested cell lines in contrast with previous statements (10) . No phosphorylation of dFdU to dFdU-MP by cytosolic TK1 was observed, consistent with the low affinity of dFdU for TK1 (41) . Possibly, dFdU is phosphorylated in part by other cytosolic enzymes and/ or by TK2 in mitochondria, which warrants further investigation.
In conclusion, the unique new findings of this study are (a) the high uptake of dFdU by hCNT1, (b) the formation of dFdU-DP and dFdU-TP from dFdC and dFdU, (c) the incorporation of dFdU-TP into DNA and RNA, and (d) the significant correlations between the AUC and DNA/ RNA incorporation of dFdC-TP/dFdU-TP and the cytotoxicity of dFdC and dFdU. High exposure levels to dFdU combined with significant phosphorylation to dFdU-TP and high levels of incorporation of dFdU-TP into DNA/RNA could contribute to the toxicity and or antitumor activity of dFdC in vivo, which warrants further investigation.
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